Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Harwood Feffer LLP
NEW YORK, July 15, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Regado Biosciences, Inc. ("Regado" or the "Company") (NASDAQ: RGDO) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
On July 3, 2014, the Company announced that patient enrollment had been paused in the Phase 3 Regulate-PCI trial of Regado's product candidate Revolixys and that a full analysis of safety and treatment benefit-risk ratio of all patients enrolled would be conducted with a focus on serious adverse events related to allergic reactions.
On July 9, 2014, the Company announced that the U.S. Food and Drug administration had informed it that a clinical hold has been placed on all patient enrollment and dosing in the ongoing Phase 3 Regulate-PCI trial.
Our investigation concerns whether the Company's officers and directors should be liable for the harm to Regado. If you own Regado shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
©2012 PR Newswire. All Rights Reserved.